Retifanlimab for advanced/metastatic merkel cell carcinoma


featured image

Merkel cell carcinoma (MCC) is a rare type of skin cancer that starts in neuroendocrine cells. Those frequently exposed to ultraviolet light and those with weakened immune systems are most at risk of developing MCC.

Therapeutic Areas: Skin Cancer
Year: 2021

Merkel cell carcinoma (MCC) is a rare type of skin cancer that starts in neuroendocrine cells. Those frequently exposed to ultraviolet light and those with weakened immune systems are most at risk of developing MCC. Symptoms include lumps on the skin, usually found where the skin is most exposed to direct sun. MCC is an aggressive cancer and can rapidly spread within weeks or months meaning early diagnosis and treatment are vital. Prognosis is poor; MCC has a high mortality rate. There are very few treatments licensed for MCC, particularly advanced/metastatic MCC which highlights the need for new treatments to improve prognosis.